@article {1050,
	title = {Neurotoxicity upon infusion of dimethylsulfoxide-cryopreserved peripheral blood stem cells in patients with and without pre-existing cerebral disease},
	journal = {European journal of haematology},
	volume = {78},
	year = {2007},
	note = {Mueller, Lutz P Theurich, Sebastian Christopeit, Maximilian Grothe, Wilfried Muetherig, Anke Weber, Thomas Guenther, Susanne Behre, Gerhard Denmark Eur J Haematol. 2007 Jun;78(6):527-31.},
	month = {Jun},
	pages = {527 - 31},
	edition = {39221},
	abstract = {OBJECTIVE: Toxicity related to the infusion of dimethylsulfoxide (DMSO)-cryopreserved peripheral blood stem cells (DMSO-PBSC) mainly comprises cardiovascular events. Fatal neurotoxicity has been reported in a few cases. DMSO represents the putative causative agent of such rare toxicities and elaborate strategies to replace DMSO would benefit from the identification of predisposing factors for DMSO-related toxicities. METHODS: Here, we report on DMSO-related neurotoxicity in a series of patients (n = 51) receiving DMSO-PBSC. The analyzed patient-series included eight patients with pre-existing cerebral disease, partially with a history of epileptic seizures. RESULTS: Neurotoxicity was observed in only one patient who suffered from a generalized tonic seizure upon infusion of DMSO-PBSC and for which the clinical course is reported herein. No neurotoxicity was observed in the group of patients with pre-existing neurological disease. Furthermore, no neurotoxicity was observed in patients who received particularly large volumes of DMSO. In all patients, mild non-neurological side effects occurred but besides the reported seizure no other severe adverse events were observed upon PBSC-infusion. CONCLUSIONS: To our knowledge, this is the first report addressing the identification of predisposing factors for DMSO-related neurotoxicty. We conclude that infusion of DMSO-PBSC can be performed safely in patients with pre-existing cerebral disease despite the rare occurrence of severe neurotoxicity. Retrospective multicenter studies are warranted to identify patients who would benefit from elaborate methods of DMSO-replacement.},
	keywords = {*Stem Cell Transplantation, Adult, Aged, Brain Diseases / *therapy, Cryopreservation, Dimethyl Sulfoxide / *toxicity, Female, Humans, Male, Middle Aged},
	issn = {0902-4441 (Print) 0902-4441 (Linking)},
	doi = {10.1111/j.1600-0609.2007.00851.x},
	author = {Mueller,L. P. and Theurich,S. and Christopeit,M. and Grothe,W. and Muetherig,A. and Weber,T. and Guenther,S. and Behre,G.}
}
